528
Participants
Start Date
July 10, 2018
Primary Completion Date
February 14, 2023
Study Completion Date
November 7, 2024
Alectinib
Alectinib will be administered orally at the label-recommended dose (600 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
Vismodegib
Vismodegib will be administered orally at the label-recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
Ipatasertib
Ipatasertib will be administered orally at the label-recommended dose (400 mg) once daily on Days 1-21 of each 28-day Cycle in combination with paclitaxel, and as monotherapy after the final administration of paclitaxel, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
Olaparib
Olaparib will be administered orally at the label-recommended dose (400 mg) twice daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
Erlotinib
Erlotinib will be administered orally in combination with Bevacizumab at the label recommended dose (150 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Bevacizumab
Bevacizumab will be administered intravenously at 15mg/kg every 3 weeks in combination with Erlotinib until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Vemurafenib
Vemurafenib will be administered orally, 960 mg twice daily, in combination with Cobimetinib, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Cobimetinib
Cobimetinib will be administered orally, 60mg once daily, in combination with Vemurafenib, on Days 1-21 of each 28-day Cycle, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Trastuzumab Subcutaneous (SC)
Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Pertuzumab
Pertuzumab will be initially be administered intravenously, 840 mg, followed by 420 mg every 3 weeks, in combination with Trastuzumab and chemotherapy, until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months)
Atezolizumab
Atezolizumab will be administered intravenously at the label-recommended dose (1200 mg), alone or in combination with chemotherapy, every 3 weeks until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
Carboplatin
Carboplatin will be administered intravenously at the area under the curve (AUC) dose once every 3 weeks for up to 9 Cycles (Cycle = 21 days) in some combination with the following: Paclitaxel, Gemcitabine, Atezolizumab, Pertuzumab, and Trastuzumab SC.
Paclitaxel
Paclitaxel will be administered intravenously, 175 mg/m\^2, once every 3 weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Carboplatin, Ipatasertib, Atezolizumab, Pertuzumab, and Trastuzumab SC
Cisplatin
Cisplatin will be administered intravenously, 60-75 mg/m\^2, once every three weeks, for up to 9 cycles (Cycle = 21 days) in some combination with the following: Gemcitabine, Paclitaxel, Atezolizumab, Pertuzumab, and Trastuzumab SC.
Gemcitabine
Gemcitabine will be administered intravenously, 1000 mg/m\^2, twice every three weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Cisplatin, Carboplatin, Atezolizumab, Pertuzumab, and Trastuzumab SC.
Entrectinib
Entrectinib will be administered orally at the label-recommended dose (600 mg) once daily until loss of clinical benefit or unacceptable toxicity, through the end of the study (approximately 70 months).
Ivosidenib
Ivosidenib will be administered orally at the label-recommended dose (500mg) once daily across a 28-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
Pemigatinib
Pemigatinib will be administered orally at the label-recommended dose (13.5mg) once daily across a 21-day treatment cycle until loss of clinical benefit or unacceptable toxicity.
Oncosalud Sac, Lima
Medizinische Universität Wien, Vienna
Orszagos Onkologiai Intezet, Budapest
Budapesti Uzsoki Utcai Kórház, Budapest
MHAT Nadezhda, Sofia
Akershus universitetssykehus HF, Lørenskog
MBAL Serdika EOOD, Sofia
GenesisCare North Shore, St Leonards
Rigshospitalet, København Ø
Peter MacCallum Cancer Center, Melbourne
Universitaetsspital Basel, Basel
Icon Cancer Foundation, South Brisbane
Sørlandet Sykehus Kristiansand, Kristiansand
Lkh Salzburg - Univ. Klinikum Salzburg, Salzburg
Flinders Medical Centre, Bedford Park
Bács-Kiskun Vármegyei Oktatókórház, Kecskemét
Lkh-Univ. Klinikum Graz, Graz
UniversitätsSpital Zürich, Zurich
Aarhus Universitetshospital, Aarhus N
Clinical Hospital Centre Zagreb, Zagreb
Ramathibodi Hospital;Medicine/Oncology, Bangkok
Faculty of Med. Siriraj Hosp., Bangkok
Clinica del Country, Bogotá
Institut Paoli-Calmettes, Marseille
Charité-Universitätsm. Berlin, Berlin
North Estonia Medical Centre, Oncology and hematology Clinic, Tallinn
CRLCC-Francois Baclesse, Caen
Instituto Nacional de Enfermedades Neoplasicas, Lima
Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda), Milan
Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi, Edirne
RED-Oncology GmbH, Oldenburg / Holstein
Asst Papa Giovanni XXIII, Bergamo
CHRU Besançon, Besançon
Hospital Ramon y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Clinico Universitario Virgen de la Victoria, Málaga
Complejo Hospitalario de Navarra, Pamplona
Institut Bergonie, Bordeaux
Tampere University Hospital, Tampere
Istanbul University Cerrahpa?a-Cerrahpa?a Medical Faculty, Istanbul
Institut régional du Cancer Montpellier, Montpellier
Centre Eugene Marquis, Rennes
IRCCS Istituto Oncologico Veneto (IOV), Padua
?zmir Medical Point, Kar?iyaka
Complexo Hospitalario de Vigo. Hospital Álvaro Cunqueiro, Vigo
Hospital Universitario Virgen Macarena, Seville
Arcispedale Santa Maria Nuova, Reggio Emilia
Kliniken Essen-Mitte, Evang. Huyssens-Stiftung, Klinik für Internistische Onkologie / Haematologie, Essen
Hospital Universitari i Politecnic La Fe, Valencia
Universitätsklinikum Münster, Medizinische Klinik A, Translationale Onkologie, Münster
Ico - Paul Papin, Angers
Hospital Universitario Miguel Servet, Zaragoza
U. O. Oncologia Medica, Ospedale Santa Chiara, Pisa
Universitätsklinikum Frankfurt, UCT, Frankfurt
Centre Jean Perrin Centre Regional de Lutte Contre Le Cancer D auvergne, Clermont-Ferrand
AVIX Investigación Clínica S.C, Monterrey
CHU Strasbourg Hôpital Hautepierre, Strasbourg
Klinikum Mannheim III. Medizinische Klinik, Mannheim
Centre Leon Berard, Lyon
Universitätsklinikum Heidelberg, Heidelberg
CHU Lyon - Centre Hospitalier Lyon Sud, Pierre-Benite (Lyon)
SLK-Kliniken Heilbronn GmbH;Klinik für Innere Medizin III, Heilbronn
Institut Curie, Paris
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli
Klinikum der LMU München, Campus Großhadern, Krebszentrum München, München
Onkologisches Zentrum - Onkologie Dachau, Dachau
Universitätsklinikum Augsburg, Augsburg
Policlinico Univ. - A.O. Mater Domini, Catanzaro
Hopital Foch, Suresnes
Institut Gustave Roussy, Villejuif
Centrul de Oncologie Sfantul Nectarie, Craiova
Oncomedica S.A., Montería
Oncocenter Timisoara, Timi?oara
Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca, Cluj-Napoca
Institutul Regional de Oncologie Iasi, Iași
James Lind Centro de Investigación Del Cáncer, Temuco
Rabin MC, Petah Tikva
Chaim Sheba medical center, Oncology division, Ramat Gan
Tel Aviv Sourasky Medical Ctr, Tel Aviv
Bradford Hill Centro de Investigaciones Clinicas, Recoleta
Blacktown Hospital, Blacktown
Hospital Sao Rafael - HSR, Salvador
Hospital de Cancer de Barretos, Barretos
Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo
Instituto Nacional de Cancer - INCa, Rio de Janeiro
Inst. Nacional de Cancerologia, Bogotá
Masarykuv onkologicky ustav, Brno
Fakultni nemocnice Olomouc, Olomouc
Fakultni Poliklinika Vseobecne Fakultni Niemocnice, Prague
Helsinki University Central Hospital, Helsinki
Centre Antoine Lacassagne, Nice
"Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden", Dresden
Universitätsklinikum Jena, Klinik für Innere Medizin II, Jena
Anticancer Hospital Ag Savas, Athens
IASO General Hospital of Athens, Athens
Univ General Hosp Heraklion, Heraklion
Uni Hospital of Ioannina, Ioannina
Theagenio Anticancer Hospital, Thessaloniki
St Vincent'S Uni Hospital, Dublin
Waterford Regional Hospital, Waterford
National Cancer Center Hospital East, Chiba
National Hospital Organization Kyushu Cancer Center, Fukuoka
Riga East Clinical University Hospital Latvian Oncology Centre, Riga
Health Pharma Professional Research, CD Mexico
Erasmus MC, Rotterdam
Universitair Medisch Centrum Utrecht, Utrecht
Ziekenhuis VieCuri Medisch Centrum, Venlo
Oslo universitetssykehus HF, Ullevål, Kreftsenteret, Oslo
Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii, Krakow
IPO do Porto, Porto
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Hospital Sant Joan Despi- Moises Broggi, Sant Joan Despí
Hospital Clínic i Provincial, Barcelona
Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona
Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital, Adana
Ankara University Medical Faculty, Ankara
Hacettepe Uni Medical Faculty Hospital, S?hhiye, Ankara
Ankara Oncology Hospital, Ankara
Akdeniz University Medical Faculty, Antalya
Royal United Hospital, Bath
Velindre Cancer Centre, Cardiff
Western General Hospital, Edinburgh
Hammersmith Hospital, London
Christie Hospital NHS Trust, Manchester
Freeman Hospital, Newcastle upon Tyne
Southampton General Hospital, Southampton
Torbay Hospital, Torquay
Collaborators (1)
Foundation Medicine
INDUSTRY
Hoffmann-La Roche
INDUSTRY